The Trump administration is easing deadlines for large pharmaceutical companies to meet investment commitments tied to most favoured nation agreements, Endpoints News reported. Exact US investment amounts are still being negotiated, though at least one drugmaker expects to fulfil its multibillion-dollar pledge by January 1, 2029.